WEST CHESTER, Ohio, Jan. 31 /PRNewswire-FirstCall/ -- AtriCure, Inc. , a medical device company focused on developing, manufacturing and selling innovative surgical devices, will release its financial results for the quarter and year ended December 31, 2006 on Thursday, February 15, 2007 after the close of the U.S. financial markets.
AtriCure will also host a Web cast and conference call at 5:00 pm ET on February 15, 2007 to discuss fourth quarter and full year 2006 results. A live Web cast of the conference call will be available online from the investor relations page of AtriCure’s corporate Web site at www.atricure.com. The dial-in numbers are (866) 770-7125 for domestic callers, and (617) 213-8066 for international callers. The reservation number for both is 69505716.
A recording of the conference call will remain available on AtriCure’s Web site through March 15, 2007. A telephonic replay of the call will be available until March 30, 2007. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Please use reservation code 85966642.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft and cardiac tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a rapid, irregular quivering of the upper chambers of the heart. atrial fibrillation affects more than 2.4 million people in the U.S. and predisposes them to a five fold increased risk of stroke.
The FDA has cleared the AtriCure bipolar ablation system for the ablation, or destruction, of soft tissues in general and non-cardiac related surgical procedures but to date has not cleared or approved the system for cardiac use or for the treatment of AF.
The FDA has cleared the AtriCure Isolator(TM) Transpolar(TM) Pen for the ablation of cardiac tissue and the evaluation of cardiac arrhythmias, but the Isolator(TM) Transpolar(TM) Pen has not been approved for the treatment of AF.
Contacts: AtriCure, Inc. The Ruth Group Julie A. Piton Nick Laudico (investors) Vice President and Chief Financial Officer (646) 536-7030 (513) 755-4561 nlaudico@theruthgroup.comjpiton@atricure.com Jason Rando (media) (646) 536-7025 jrando@theruthgroup.com
AtriCure, Inc.
CONTACT: Julie A. Piton, Vice President and Chief Financial Officer,AtriCure, Inc., +1-513-755-4561, jpiton@atricure.com; or Nick Laudico(investors), +1-646-536-7030, nlaudico@theruthgroup.com, or Jason Rando(media), +1-646-536-7025, jrando@theruthgroup.com, both of The Ruth Group
Web site: http://www.atricure.com/
